Molecular Biology Reports

, Volume 41, Issue 11, pp 7033–7041 | Cite as

Modulation of cysteine-rich protein 2 expression in vascular injury and atherosclerosis

  • Chung-Huang Chen
  • Hua-Hui Ho
  • Meng-Ling Wu
  • Matthew D. Layne
  • Shaw-Fang Yet


Vascular smooth muscle cells (VSMCs) of the arterial wall normally display a differentiated and contractile phenotype. In response to arterial injury, VSMCs switch to a synthetic phenotype, contributing to vascular remodeling. Cysteine-rich protein 2 (CRP2) is a cytoskeletal protein expressed in VSMCs and blunts VSMC migration in part by sequestering the scaffolding protein p130Cas at focal adhesions. CRP2 deficiency in mice increases neointima formation following arterial injury. The goal of this study was to use Csrp2 promoter-lacZ transgenic mice to analyze CRP2 expression during VSMC phenotypic modulation. In a neointima formation model after carotid artery cessation of blood flow, lacZ reporter activity and smooth muscle (SM) α-actin expression in the media were rapidly downregulated 4 days after carotid ligation. Fourteen days after ligation, there was a high level expression of both Csrp2 promoter activity and SM α-actin protein expression in neointimal cells. In atherosclerosis prone mice fed an atherogenic diet, Csrp2 promoter activity was detected within complex atherosclerotic lesions. Interestingly, Csrp2 promoter activity was also present in the fibrous caps of complicated atherosclerotic lesions, indicating that CRP2 might contribute to plaque stability. These findings support the concept that CRP2 contributes to the phenotypic modulation of VSMCs during vascular disease. Modulating transcription to increase CRP2 expression during vascular injury might attenuate vascular remodeling. In addition, increased CRP2 expression at the fibrous caps of advanced lesions might also serve to protect atherosclerotic plaques from rupture.


Cysteine-rich protein 2 Vascular smooth muscle cells Transgenic mice Vascular injury Atherosclerosis 



This work was supported by grants from the National Science Council, Taiwan (101-2320-B-400-002-MY3 to S.-F.Y.), National Health Research Institutes (CS-103-PP-05 to S.-F.Y.), and the National Institutes of Health (HL-078869 to M.D.L.). This research was conducted under the Graduate Program of Biotechnology in Medicine sponsored by the National Tsing Hua University and the National Health Research Institutes. We thank the Pathology Core Laboratory of the National Health Research Institutes for processing and embedding of tissue samples. We thank Wun-Chu Fan for assistance in histological analysis.


  1. 1.
    Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84(3):767–801PubMedCrossRefGoogle Scholar
  2. 2.
    Louis HA, Pino JD, Schmeichel KL, Pomies P, Beckerle MC (1997) Comparison of three members of the cysteine-rich protein family reveals functional conservation and divergent patterns of gene expression. J Biol Chem 272(43):27484–27491PubMedCrossRefGoogle Scholar
  3. 3.
    Arber S, Caroni P (1996) Specificity of single LIM motifs in targeting and LIM/LIM interactions in situ. Genes Dev 10(3):289–300PubMedCrossRefGoogle Scholar
  4. 4.
    Jain MK, Fujita KP, Hsieh CM, Endege WO, Sibinga NE, Yet SF, Kashiki S, Lee WS, Perrella MA, Haber E, Lee ME (1996) Molecular cloning and characterization of SmLIM, a developmentally regulated LIM protein preferentially expressed in aortic smooth muscle cells. J Biol Chem 271(17):10194–10199PubMedCrossRefGoogle Scholar
  5. 5.
    Yet SF, Folta SC, Jain MK, Hsieh CM, Maemura K, Layne MD, Zhang D, Marria PB, Yoshizumi M, Chin MT, Perrella MA, Lee ME (1998) Molecular cloning, characterization, and promoter analysis of the mouse Crp2/SmLim gene: preferential expression of its promoter in the vascular smooth muscle cells of transgenic mice. J Biol Chem 273(17):10530–10537PubMedCrossRefGoogle Scholar
  6. 6.
    Chang YF, Wei J, Liu X, Chen YH, Layne MD, Yet SF (2003) Identification of a CArG-independent region of the cysteine-rich protein 2 promoter that directs expression in the developing vasculature. Am J Physiol Heart Circ Physiol 285(4):H1675–H1683PubMedGoogle Scholar
  7. 7.
    Chen CH, Ho YC, Ho HH, Chang IC, Kirsch KH, Chuang YJ, Layne MD, Yet SF (2013) Cysteine-rich protein 2 alters p130Cas localization and inhibits vascular smooth muscle cell migration. Cardiovasc Res 100(3):461–471PubMedCrossRefGoogle Scholar
  8. 8.
    Wei J, Gorman TE, Liu X, Ith B, Tseng A, Chen Z, Simon DI, Layne MD, Yet SF (2005) Increased neointima formation in cysteine-rich protein 2-deficient mice in response to vascular injury. Circ Res 97(12):1323–1331PubMedCrossRefGoogle Scholar
  9. 9.
    Chen CH, Wu ML, Lee YC, Layne MD, Yet SF (2010) Intronic CArG box regulates cysteine-rich protein 2 expression in the adult but not in developing vasculature. Arterioscler Thromb Vasc Biol 30(4):835–842PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ (1997) Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation 96(12):4333–4342PubMedCrossRefGoogle Scholar
  11. 11.
    Perrella MA, Pellacani A, Layne MD, Patel A, Zhao D, Schreiber BM, Storch J, Feinberg MW, Hsieh CM, Haber E, Lee ME (2001) Absence of adipocyte fatty acid binding protein prevents the development of accelerated atherosclerosis in hypercholesterolemic mice. FASEB J 15(10):1774–1776PubMedGoogle Scholar
  12. 12.
    Yet SF, Layne MD, Liu X, Chen YH, Ith B, Sibinga NE, Perrella MA (2003) Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J 17(12):1759–1761PubMedGoogle Scholar
  13. 13.
    Kumar A, Lindner V (1997) Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 17(10):2238–2244PubMedCrossRefGoogle Scholar
  14. 14.
    Passman JN, Dong XR, Wu SP, Maguire CT, Hogan KA, Bautch VL, Majesky MW (2008) A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells. Proc Natl Acad Sci USA 105(27):9349–9354PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Smith RL, Geller AI, Escudero KW, Wilcox CL (1995) Long-term expression in sensory neurons in tissue culture from herpes simplex virus type 1 (HSV-1) promoters in an HSV-1-derived vector. J Virol 69(8):4593–4599PubMedPubMedCentralGoogle Scholar
  16. 16.
    Doran AC, Meller N, McNamara CA (2008) Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 28(5):812–819PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Regan CP, Adam PJ, Madsen CS, Owens GK (2000) Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. J Clin Invest 106(9):1139–1147PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Mack CP, Owens GK (1999) Regulation of smooth muscle α-actin expression in vivo is dependent on CArG elements within the 5′ and first intron promoter regions. Circ Res 84(7):852–861PubMedCrossRefGoogle Scholar
  19. 19.
    Miano JM, Carlson MJ, Spencer JA, Misra RP (2000) Serum response factor-dependent regulation of the smooth muscle calponin gene. J Biol Chem 275(13):9814–9822PubMedCrossRefGoogle Scholar
  20. 20.
    Manabe I, Owens GK (2001) CArG elements control smooth muscle subtype-specific expression of smooth muscle myosin in vivo. J Clin Invest 107(7):823–834PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Layne MD, Yet SF, Maemura K, Hsieh CM, Liu X, Ith B, Lee ME, Perrella MA (2002) Characterization of the mouse aortic carboxypeptidase-like protein promoter reveals activity in differentiated and dedifferentiated vascular smooth muscle cells. Circ Res 90(6):728–736PubMedCrossRefGoogle Scholar
  22. 22.
    Hendrix JA, Wamhoff BR, McDonald OG, Sinha S, Yoshida T, Owens GK (2005) 5′ CArG degeneracy in smooth muscle α-actin is required for injury-induced gene suppression in vivo. J Clin Invest 115(2):418–427PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Wamhoff BR, Hoofnagle MH, Burns A, Sinha S, McDonald OG, Owens GK (2004) A G/C element mediates repression of the SM22α promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res 95(10):981–988PubMedCrossRefGoogle Scholar
  24. 24.
    Maiellaro K, Taylor WR (2007) The role of the adventitia in vascular inflammation. Cardiovasc Res 75(4):640–648PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Feil S, Hofmann F, Feil R (2004) SM22α modulates vascular smooth muscle cell phenotype during atherogenesis. Circ Res 94(7):863–865PubMedCrossRefGoogle Scholar
  26. 26.
    Bentzon JF, Sondergaard CS, Kassem M, Falk E (2007) Smooth muscle cells healing atherosclerotic plaque disruptions are of local, not blood, origin in apolipoprotein E knockout mice. Circulation 116(18):2053–2061PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Chung-Huang Chen
    • 1
    • 2
  • Hua-Hui Ho
    • 1
  • Meng-Ling Wu
    • 1
    • 3
  • Matthew D. Layne
    • 4
  • Shaw-Fang Yet
    • 1
    • 5
  1. 1.Institute of Cellular and System MedicineNational Health Research InstitutesZhunanTaiwan
  2. 2.Institute of Bioinformatics and Structural Biology and Department of Medical ScienceNational Tsing Hua UniversityHsinchuTaiwan
  3. 3.Institute of Molecular MedicineNational Tsing Hua UniversityHsinchuTaiwan
  4. 4.Department of BiochemistryBoston University School of MedicineBostonUSA
  5. 5.Metabolomic Research Center, China Medical University Hospital and Graduate Institute of Basic Medical ScienceChina Medical UniversityTaichungTaiwan

Personalised recommendations